DHX30: A Potential Drug Target and Biomarker for Helicase-Driven Processes

Target Name: DHX30

NCBI ID: G22907

DHX30: A Potential Drug Target and Biomarker for Helicase-Driven Processes

Helicase enzymes are a class of proteins that are involved in various biochemical processes, including DNA replication, transcription, and translation. They play a crucial role in the regulation of gene expression and are often targets for drugs that aim to modulate their activity. One of the well-known helicase enzymes is DHX30 (DEAH (Asp-Glu-Ala-His) box helicase 30), which is a key enzyme in the process of DNA double-strand break repair. In this article, we will discuss DHX30 as a potential drug target and biomarker.

Potential Drug Target

DHX30 is a member of the DEAH family of helicases, which are known for their ability to repair double-strand breaks in DNA. The DEAH family includes four subfamilies, including DHX1, DHX2, DHX3, and DHX4. DHX30 is a member of the DHX3 subfamily, which is responsible for repairing DNA double-strand breaks caused by various types of damage, including radiation-induced and mutational breaks.

DHX30 is involved in the repair of both single- and double-strand breaks. It has been shown to efficiently repair double-strand breaks caused by UV radiation, where other repair enzymes are often unable to efficiently repair these breaks. Additionally, DHX30 has also been shown to repair breaks caused by other types of damage, such as those caused by chemical agents or genetic mutations.

DHX30's ability to efficiently repair double-strand breaks makes it an attractive drug target. Drugs that are able to inhibit DHX30's activity could potentially be used to treat a variety of diseases, including cancer, where double-strand breaks are often repaired incorrectly, leading to the development of cancer.

Biomarker

DHX30 can also serve as a biomarker for various diseases. For example, DHX30 has been shown to be overexpressed in various types of cancer, including breast, lung, and colon cancer. This suggests that DHX30 may be a useful biomarker for these diseases, and that inhibiting its activity could be a potential therapy.

In addition to its potential as a drug target, DHX30 may also be a useful biomarker for certain types of cancer. For example, DHX30 has been shown to be overexpressed in pancreatic cancer, which is a particularly aggressive form of cancer. This suggests that DHX30 may be a potential biomarker for pancreatic cancer, and that targeting its activity could be a potential therapy.

Conclusion

In conclusion, DHX30 is a member of the DEAH family of helicases, which are involved in various biochemical processes, including DNA replication, transcription, and translation. It is a potential drug target and biomarker for various diseases, including cancer. The inhibition of DHX30's activity could potentially lead to the development of new therapies for these diseases. Further research is needed to fully understand DHX30's role in biology and its potential as a drug target and biomarker.

Protein Name: DExH-box Helicase 30

Functions: RNA-dependent helicase (PubMed:29100085). Plays an important role in the assembly of the mitochondrial large ribosomal subunit (PubMed:25683715, PubMed:29100085). Required for optimal function of the zinc-finger antiviral protein ZC3HAV1 (By similarity). Associates with mitochondrial DNA (PubMed:18063578). Involved in nervous system development and differentiation through its involvement in the up-regulation of a number of genes which are required for neurogenesis, including GSC, NCAM1, neurogenin, and NEUROD (By similarity)

More Common Targets